Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rival

Bayer’s Sunharbo has secured the first FDA approval of its class, establishing a regulatory pathway for other factor XIa inhibitors, such as Bristol Myers Squibb and Johnson and Johnson’s milvexian.